Full text is available at the source.
Abstract
Maladaptive neurohormonal activation is a central driver in cardiorenal disease.
- Cardiorenal disease involves injury among the heart, blood vessels, kidneys, and metabolic organs.
- Despite advancements in treatment, including RAAS blockade, significant residual risk remains.
- Apelin/APJ signaling may play a role in regulating the renin-angiotensin-aldosterone system.
- Interactions between APJ and AT1R could influence pathways related to inflammation and fibrosis.
- The ACE2/Ang-(1-7)/Mas signaling pathway is associated with endothelial and metabolic protection.
- Emerging APJ agonists may offer new therapeutic avenues in managing cardiorenal disease.
Simplified